(Pharmamar) PharmaMar (MSE:PHM) has announced today the signing of an exclusive license, development and commercialization agreement with Chugai Pharmaceutical Co. Ltd. (TSE:4519) for its third marine-derived anticancer drug PM1183 (lurbinectedin) in Japan.
from EurekAlert! - Social and Behavioral Science http://ift.tt/2ifuLCG
No comments:
Post a Comment